5-HT2A receptor

Last updated

HTR2A
5ht2a.jpg
Identifiers
Aliases HTR2A , 5-HT2A, HTR2, 5-hydroxytryptamine receptor 2A
External IDs OMIM: 182135; MGI: 109521; HomoloGene: 68073; GeneCards: HTR2A; OMA:HTR2A - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3356

15558

Ensembl

ENSG00000102468

ENSMUSG00000034997

UniProt

P28223

P35363

RefSeq (mRNA)

NM_001165947
NM_000621
NM_001378924

NM_172812

RefSeq (protein)

NP_000612
NP_001159419
NP_001365853

NP_766400

Location (UCSC) Chr 13: 46.83 – 46.9 Mb n/a
PubMed search [2] [3]
Wikidata
View/Edit Human View/Edit Mouse

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and functions as a G protein-coupled receptor (GPCR). [4] It is a cell surface receptor [5] that activates multiple intracellular signalling cascades. [6] Like all 5-HT2 receptors, the 5-HT2A receptor is coupled to the Gq/G11 signaling pathway. It is the primary excitatory receptor subtype among the serotonin-responsive GPCRs. The 5-HT2A receptor was initially noted for its central role as the primary target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. It later regained research prominence when found to mediate, at least in part, the effects of many antipsychotic drugs, particularly atypical antipsychotics.

Contents

Downregulation of post-synaptic 5-HT2A receptors is an adaptive response triggered by chronic administration of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. Elevated 5-HT2A receptor density has been observed in suicidal and otherwise depressed patients, suggesting that post-synaptic 5-HT2A receptor overexpression may contribute to the pathogenesis of depression. [7] Paradoxically, several 5-HT2A receptor antagonists can also induce receptor downregulation. [8] This effect may lead to reverse tolerance, rather than the expected development of tolerance. However, at least one antagonist has been shown to upregulate 5-HT2A receptor expression, [8] [9] and a few others appear to have no effect on receptor levels. [10] Nonetheless, such upregulation remains the exception rather than the rule.

Importantly, neither tolerance nor rebound has been observed in humans in relation to the slow-wave sleep (SWS)-promoting effects of 5-HT2A antagonists. [11]

History

5-HT receptors were split into two classes by John Gaddum and Picarelli when it was discovered that some of the serotonin-induced changes in the gut could be blocked by morphine, while the remainder of the response was inhibited by dibenzyline, leading to the naming of M and D receptors, respectively. 5-HT2A is thought to correspond to what was originally described as D subtype of 5-HT receptors by Gaddum and Picarelli. [12] In the era before molecular cloning, when radioligand binding and displacement was the only major tool, spiperone and LSD were shown to label two different 5-HT receptors, and neither of them displaced morphine, leading to naming of the 5-HT1, 5-HT2 and 5-HT3 receptors, corresponding to high affinity sites from LSD, spiperone and morphine, respectively. [13] Later it was shown that the 5-HT2 was very close to 5-HT1C and thus were grouped together, renaming the 5-HT2 into 5-HT2A. Thus, the 5-HT2 receptor family is composed of three separate molecular entities: the 5-HT2A (formerly known as 5-HT2 or D), the 5-HT2B (formerly known as 5-HT2F) and the 5-HT2C (formerly known as 5-HT1C) receptors. [14]

Gene

Chromosome 13. Chromosome 13.jpeg
Chromosome 13.

The 5-HT2A receptors is coded by the HTR2A gene. In humans the gene is located on chromosome 13. The gene has previously been called just HTR2 until the description of two related genes HTR2B and HTR2C . Several interesting polymorphisms have been identified for HTR2A: A-1438G (rs6311), C102T (rs6313), and His452Tyr (rs6314). Many more polymorphisms exist for the gene. A 2006 paper listed 255. [15] [16]

Probable role in fibromyalgia as the T102C polymorphisms of the gene 5HT2A were common in fibromyalgia patients. [17]

Human HTR2A gene is thought to consist of 3 introns and 4 exons and to overlap with human gene HTR2A-AS1 which consists of 18 exons. [18] There are over 200 organisms that have orthologs with the human HTR2A. Currently, the best documented orthologs for HTR2A gene are the mouse, [19] and zebrafish. [20] There are 8 paralogs for the HTR2A gene. The HTR2A gene is known to interact and activate G-protein genes such as GNA14, GNAI1, GNAI3, GNAQ, and GNAZ. [21] These interactions are critical for cell signaling [22] [23] and homeostasis [24] in many organisms. [25]

In human brain tissue, regulation of HTR2A varies depending on the region: [18] frontal cortex, amygdala, thalamus, brain stem and cerebellum. In a paper from 2016, they found that HTR2A undergoes a variety of different splicing events, including utilization of alternative splice acceptor sites, exon skipping, rare exon usage, and intron retention. [18]

Transcriptional regulation

There are a few mechanisms of regulation for HTR2A gene such regulated by DNA methylation at particular transcript binding sites. [26] [27] Another mechanism for the correct regulation of gene expression is achieved through alternative splicing. This is a co-transcriptional process, which allows the generation of multiple forms of mRNA transcript from a single coding unit and is emerging as an important control point for gene expression. In this process, exons or introns can be either included or excluded from precursor-mRNA resulting in multiple mature mRNA variants. [28] These mRNA variants result in different isoforms which may have antagonistic functions or differential expression patterns, yielding plasticity and adaptability to the cells. [29] One study found that the common genetic variant rs6311 regulates expression of HTR2A transcripts containing the extended 5' UTR. [18]

Tissue distribution

5-HT2A is expressed widely throughout the central nervous system (CNS). [30] It is expressed near most of the serotonergic terminal rich areas, including neocortex (mainly prefrontal, parietal, and somatosensory cortex) and the olfactory tubercle [ citation needed ]. Especially high concentrations of this receptor on the apical dendrites of pyramidal cells in layer V of the cortex may modulate cognitive processes, working memory, and attention [31] [32] [33] by enhancing glutamate release followed by a complex range of interactions with the 5-HT1A, [34] GABAA, [35] adenosine A1, [36] AMPA, [37] mGluR2/3, [38] mGlu5, [39] and OX2 receptors. [40] [41] In the rat cerebellum, the protein has also been found in the Golgi cells of the granular layer, [42] and in the Purkinje cells. [43] [44]

In the periphery, it is highly expressed in platelets and many cell types of the cardiovascular system, in fibroblasts, and in neurons of the peripheral nervous system. Additionally, 5-HT2A mRNA expression has been observed in human monocytes. [45] Whole-body distribution of the 5-HT2A/2C receptor agonist, [11C]Cimbi-36 show uptake in several internal organs and brown adipose tissue (BAT), but it is not clear if this represents specific 5-HT2A receptor binding. [46]

Structure

The 5-HT2A receptor is a member of the class A (rhodopsin-like) G protein-coupled receptor (GPCR) family, characterized by seven transmembrane α-helices connected by extracellular and intracellular loops. [47] [48] Its ligand-binding pocket is composed of two adjacent subpockets: the orthosteric binding pocket (OBP) and an extended binding pocket (EBP), with a unique side-extended cavity near the orthosteric site that distinguishes it from related receptors. [49] [50] Ligands are anchored primarily through a conserved aspartate residue (D155^3.32) that interacts with their charged amine groups, while additional interactions involve hydrophobic contacts and hydrogen bonds with residues in both the OBP and EBP. [50] [51] Structural studies reveal that the receptor undergoes significant conformational changes upon activation, particularly in transmembrane helices 3 and 6, which facilitate G protein coupling and signal transduction. [47] [50] The extracellular ligand-binding pocket is closed by a flexible “lid,” and the intracellular region includes a short helix (H8) stabilized by π-stacking interactions, both of which contribute to the receptor's dynamic conformational landscape. [50] These structural features underlie the receptor's ability to recognize diverse ligands and mediate complex signaling behaviors.

The cryo-EM structures of the serotonin 5-HT2A receptor with a variety of serotonin 5-HT2A receptor agonists, including the tryptamines serotonin (neurotransmitter and endogenous agonist), psilocin (psychedelic), and dimethyltryptamine (DMT) (psychedelic), the lysergamides LSD (psychedelic) and 2-bromo-LSD (BOL-148) (non-hallucinogenic), and the phenethylamines mescaline (psychedelic) and RS130-180 (β-arrestin-biased agonist with unknown hallucinogenic potential), have been solved and published by Bryan Roth and colleagues. [52] [53]

Function

The 5-HT2A receptor is a subtype of serotonin receptor that plays a critical role in the central nervous system, particularly in regions involved in cognition, learning, and memory. [54] It is highly expressed in the cerebral cortex, especially in layer V pyramidal neurons and certain interneurons, where it modulates thalamocortical information processing and may influence gamma oscillations, which are important for sensory integration and perception. [55] Functionally, the 5-HT2A receptor is a G protein-coupled receptor (GPCR) that primarily signals through the phospholipase C (PLC) pathway, leading to the production of inositol triphosphate (IP3) and diacylglycerol, but it can also activate other signaling cascades such as arachidonic acid and 2-arachidonylglycerol pathways. [55] Notably, the receptor exhibits "functional selectivity," meaning different ligands can differentially activate these signaling pathways, which is relevant for the distinct effects of hallucinogens, antipsychotics, and antidepressants that target the receptor. [55] [51] Activation of the 5-HT2A receptor by agonists is associated with enhanced cognition and hallucinogenic effects, while antagonists have antipsychotic and antidepressant properties. [54] Dysregulation of 5-HT2A receptor function has been implicated in psychiatric disorders such as depression, schizophrenia, and drug addiction. [54] Additionally, the receptor undergoes unique regulatory processes, including desensitization and internalization that are partly independent of β-arrestin, further distinguishing it from other GPCRs and influencing its response to long-term pharmacological modulation. [55]

Signaling cascade

The 5-HT2A receptor is known primarily to couple to the Gαq signal transduction pathway. Upon receptor stimulation with agonist, Gαq and β-γ subunits dissociate to initiate downstream effector pathways. Gαq stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol  (DAG) and inositol triphosphate  (IP3), which in turn stimulate protein kinase C  (PKC) activity and Ca2+ release. [56]

Effects

Physiological processes mediated by the receptor include:

Ligands

Agonists

Activation of the 5-HT2A receptor is necessary for the effects of the "classic" psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched. [70] [71] Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Some findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors. [72] [73] [57] However, newer research suggests that 5HT2A and mGlu2 receptors do not physically associate with each other, so the former findings have questionable relevance. [74] Agonists enhance dopamine in PFC, [33] enhance memory and play an active role in attention and learning. [75] [76]

Serotonin 5-HT2A receptor agonists include serotonergic psychedelics [77] and non-hallucinogenic agents. [78] [79] Psychedelics have widely been encountered as recreational drug or drugs of misuse, with potential clinical consequences such as overdose, hospitalization, bad trips and worsened mental health, and rare adverse effects such as seizures, psychosis, and hallucinogen persisting perception disorder (HPPD). [80] [81] On the other hand, psychedelics and non-hallucinogenic serotonin 5-HT2A receptor agonists are under development as novel treatments for psychiatric disorders like depression, anxiety, and addiction as well as other conditions like cluster headaches. [82] [83] [84] [85] [86] Both psychedelics and non-hallucinogenic serotonin 5-HT2A receptor agonists are claimed to act as psychoplastogens and this might be involved in their therapeutic effects. [85] [87] [88]

Anti-inflammatory effects

Various serotonergic psychedelics, acting as serotonin 5-HT2A receptor agonists, have been found to be highly potent and efficacious anti-inflammatory and immunomodulatory agents in preclinical research (i.e., animal and in-vitro studies). [89] [90] [91] [92] [93] [94] [95] In contrast to corticosteroids however, psychedelics with anti-inflammatory effects do not appear to suppress the immune system. [89] [90] Some psychedelics have been found to be far more potent in their anti-inflammatory effects than in their psychedelic effects. [91] [92] For instance, (R)-DOI is 30- to >50-fold more potent in producing anti-inflammatory effects than in producing psychedelic-like behavioral effects in animal research. [91] [92] [90] Psilocin, the active form of psilocybin, has similar anti-inflammatory potency as (R)-DOI. [90] [91] [95]

The potencies of psychedelics and other serotonin 5-HT2A receptor agonists as anti-inflammatory drugs vary, with 2C-I, DOIB, 2C-B, 4-HO-DiPT, DOI, 2,5-DMA, DOET, DOM, psilocin, and 2C-H being highly potent and fully efficacious anti-inflammatories; TMA-2, 2C-B-Fly, TCB-2, ETH-LAD, LSD, and 2C-T-33 being partially efficacious anti-inflammatories; and lisuride, 1-methylpsilocin, 5-MeO-DMT, and DMT having negligible efficacy. [90] [95] Both non-hallucinogenic agents with full anti-inflammatory effects, such as 2,5-DMA, and non-anti-inflammatory agents with full psychedelic effects, such as DOTFM, are known. [95] [96] [97] Hence, the psychedelic and anti-inflammatory effects of serotonin 5-HT2A receptor agonists appear to be fully dissociable. [95] [96] [97] These effects appear to be mediated by different intracellular signaling pathways, although the exact pathways are unclear. [97]

Serotonin 5-HT2A receptor agonists with anti-inflammatory effects but reduced psychedelic effects, such as 2C-iBu (ELE-02), are under development for the potential treatment of inflammatory conditions. [98] [99] [100] They may also have applications in the treatment of neuroinflammation. [89] [92] The anti-inflammatory effects of psychedelics might be involved in the claimed effects of psychedelic microdosing. [101] [102] Relatedly, LSD microdosing is being studied in the treatment of Alzheimer's disease specifically for its anti-inflammatory effects. [103] [104]

Full agonists

Partial agonists

Selective agonists

Peripherally selective agonists

One effect of 5-HT2A receptor activation is a reduction in intraocular pressure, and so 5-HT2A agonists can be useful for the treatment of glaucoma. This has led to the development of compounds such as AL-34662 that are hoped to reduce pressure inside the eyes but without crossing the blood–brain barrier and producing hallucinogenic side effects. [139] Animal studies with this compound showed it to be free of hallucinogenic effects at doses up to 30 mg/kg, although several of its more lipophilic analogues did produce the head-twitch response known to be characteristic of hallucinogenic effects in rodents. [140]

Antagonists

Serotonin 5-HT2A receptor antagonists, including many atypical antipsychotics, more selective agents like pimavanserin, and certain antidepressants and hypnotics like trazodone, mirtazapine, tricyclic antidepressants, and hydroxyzine, are used in the treatment of psychiatric disorders and other conditions such as depression, anxiety, psychosis, and insomnia. [141] [142] [143] Ketanserin, a dual serotonin 5-HT2A receptor antagonist and α1-adrenergic receptor antagonist, is used as an antihypertensive agent. [144] [143] The non-selective serotonin 5-HT2A receptor antagonist cyproheptadine is frequently used off-label to treat serotonin syndrome, albeit based on limited clinical evidence. [145] [146] [147] Serotonin 5-HT2A receptor antagonists like ketanserin have been used as psychedelic antidotes or "trip killers" to manage the hallucinogenic effects of serotonergic psychedelics. [148] [149] [150]

List of antagonists

Peripherally selective antagonists

Antagonists and cardiovascular disease

Increased 5-HT2A expression is observed in patients with coronary thrombosis, and the receptor has been associated with processes that influence atherosclerosis. [162] As the receptor is present in coronary arteries [163] and capable of mediating vasoconstriction, 5-HT2A has also been linked to coronary artery spasms. [164] 5-HT antagonism, therefore, has potential in the prevention of cardiovascular disease, however, no studies have been published so far. [162]

Inverse agonists

Positive allosteric modulators

Positive allosteric modulators of the serotonin 5-HT2A receptor have been identified. [173] [174] These include CTW0404 and CTW0419. [173] [174] They selectively potentiated the serotonin 5-HT2A receptor without affecting the serotonin 5-HT2B and 5-HT2C receptors. [173] [174] Unlike serotonin 5-HT2A receptor agonists, they did not substitute for the serotonergic psychedelic (R)-DOI in drug discrimination tests and did not produce the head-twitch response, suggesting that they lack hallucinogenic effects. [173] [174] Instead, they blunted the (R)-DOI-induced head-twitch response. [174] The (R)-enantiomer of glaucine has also been reported to be a serotonin 5-HT2A receptor positive allosteric modulator. [175] A dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator is the oleamide analogue JPC0323. [176] [177]

Functional selectivity

5-HT2A-receptor ligands may differentially activate the transductional pathways (see above). Studies evaluated the activation of two effectors, PLC and PLA2, by means of their second messengers. Compounds displaying more pronounced functional selectivity are 2,5-DMA and 2C-N. The former induces IP accumulation without activating the PLA2 mediated response, while the latter elicits AA release without activating the PLC mediated response. [178]

2,5-DMA.svg 2C-N.png

Recent research has suggested potential signaling differences within the somatosensory cortex between 5-HT2A agonists that produce headshakes in the mouse and those that do not, such as lisuride, as these agents are also non-hallucinogenic in humans despite being active 5-HT2A agonists. [179] [180] One known example of differences in signal transduction is between the two 5-HT2A agonists serotonin and DOI that involves differential recruitment of intracellular proteins called β-arrestins, more specifically arrestin beta 2. [181] [182] Cyclopropylmethanamine derivatives such as (−)-19 have also been shown to act as 5-HT2A/2C agonists with functional selectivity for Gq-mediated signaling compared with β-arrestin recruitment. [183]

Serotonin-elevating drugs

Besides direct serotonin 5-HT2A receptor agonists, many drugs elevate serotonin levels and indirectly activate serotonin 5-HT2A receptors. [184] [185] Examples include antidepressants and anxiolytics such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and serotonin precursors like tryptophan and 5-hydroxytryptophan (5-HTP). [184] [185] In addition, serotonin releasing agents (SRAs), including appetite suppressants like fenfluramine and chlorphentermine and entactogens like MDMA, elevate serotonin levels and indirectly activate serotonin 5-HT2A receptors similarly. [186] [187] [188] [189] [190] [191] Serotonin 5-HT2A receptor activation may be involved in the therapeutic effects of serotonin-elevating medications [184] [185] and appears to be importantly involved in the subjective effects of SRAs like MDMA. [149] Serotonin-elevating drugs can cause serotonin syndrome under certain circumstances, for instance in overdose or with combination of multiple serotonergic drugs, and the serotonin 5-HT2A receptor appears to be a key serotonin receptor in mediating this syndrome. [192] [193] [194]

Methods to analyse the receptor

The receptor can be analysed by neuroimaging, radioligand, genetic analysis, measurements of ion flows, and other ways.[ citation needed ]

Neuroimaging

The 5-HT2A receptors may be imaged with PET-scanners using the fluorine-18-altanserin, [195] MDL 100,907 [196] or [11C]Cimbi-36 [105] [197] radioligands that binds to the neuroreceptor, e.g., one study reported a reduced binding of altanserin particularly in the hippocampus in patients with major depressive disorder. [198]

Altanserin uptake decreases with age reflecting a loss of specific 5-HT2A receptors with age. [199] [200] [201]

Other

Western blot with an affinity-purified antibody and examination of 5-HT2A receptor protein samples by electrophoresis has been described. Immunohistochemical staining of 5-HT2A receptors is also possible. [5]

Clinical significance

Associations with psychiatric disorders

Several studies have seen links between the -1438G/A polymorphism and mood disorders, such as major depressive disorder. [202] and a strong link with an odds ratio of 1.3 has been found between the T102C polymorphism and schizophrenia. [203]

The T102C polymorphism has also been studied in relation to suicide attempts, with a study finding excess of the C/C genotype among the suicide attempters. [204] A number of other studies were devoted to finding an association of the gene with schizophrenia, with diverging results. [205]

These individual studies may, however, not give a full picture: A review from 2007 looking at the effect of different SNPs reported in separate studies stated that "genetic association studies [of HTR2A gene variants with psychiatric disorders] report conflicting and generally negative results" with no involvement, small or a not replicated role for the genetic variant of the gene. [206]

Polymorphisms in the promoter gene coding Early growth response 3 (EGR3) are associated with schizophrenia. Studies have demonstrated a relationship between EGR3 and HTR2A, and schizophrenia-like behaviors in transgenic animals. [207] [208] Exactly how these results translate over to further biopsychological understanding of schizophrenia is still widely debated. [209] [210] There is some evidence that dysfunction of HTR2A can impact pharmacological interventions. [211]

Several studies have assessed a relationship between 5-hydroxytryptamine (serotonin) 2A receptor (5-HTR2A) gene polymorphisms with an increased risk of suicidal behavior. One study revealed that T102C polymorphism is associated with suicidal behavior [212] but other studies failed to replicate these findings and found no association between polymorphism and suicidal behavior. [213]

Treatment response

Genetics seems also to be associated to some extent with the amount of adverse events in treatment of major depression disorder. [214]

Associations with substance abuse

Polymorphisms in the 5-HT2A receptor coding gene HTR2A (rs6313 and s6311) have been shown to have conflicting associations with alcohol misuse. For example, A polymorphism in the 5-HT2A receptor coding gene HTR2A (rs6313) was reported to predict lower positive alcohol expectancy, higher refusal self-efficacy, and lower alcohol misuse in a sample of 120 young adults. However, this polymorphism did not moderate the linkages between impulsivity, cognition, and alcohol misuse. [215] There are conflicting results as other studies have found associations between T102C polymorphisms alcohol misuse. [216] [217]

Drug impact on gene expression

There is some evidence that methylation patterns may contribute to relapse behaviors in people who use stimulants. [218] In mice, psychotropic drugs such as DOI, LSD, DOM, and DOB which produced differing transcriptional patterns among several different brain regions. [208]

See also

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000102468 – Ensembl, May 2017
  2. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ Cook EH, Fletcher KE, Wainwright M, Marks N, Yan SY, Leventhal BL (August 1994). "Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor". Journal of Neurochemistry. 63 (2): 465–469. doi:10.1046/j.1471-4159.1994.63020465.x. PMID   8035173. S2CID   40207336.
  5. 1 2 3 Kling A (2013). 5-HT2A: a serotonin receptor with a possible role in joint diseases (PDF) (Ph.D. thesis). Umeå, Sweden: Umeå Universitet. ISBN   978-91-7459-549-9.
  6. ↑ Raote I (2007). "Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways". Ishier. Frontiers in Neuroscience. Press/Taylor & Francis. ISBN   9780849339776. PMID   21204452.
  7. ↑ Eison AS, Mullins UL (1996). "Regulation of central 5-HT2A receptors: a review of in vivo studies". Behavioural Brain Research. 73 (1–2): 177–181. doi:10.1016/0166-4328(96)00092-7. PMID   8788498. S2CID   4048975.
  8. 1 2 Yadav PN, Kroeze WK, Farrell MS, Roth BL (October 2011). "Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo". The Journal of Pharmacology and Experimental Therapeutics. 339 (1): 99–105. doi:10.1124/jpet.111.183780. PMC   3186284 . PMID   21737536.
  9. ↑ Rinaldi-Carmona M, Congy C, Simiand J, Oury-Donat F, Soubrie P, Breliere JC, et al. (January 1993). "Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain". Molecular Pharmacology. 43 (1): 84–89. doi:10.1016/S0026-895X(25)13451-2. PMID   8423772.
  10. ↑ Gray JA, Roth BL (November 2001). "Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists". Brain Research Bulletin. 56 (5): 441–451. doi:10.1016/s0361-9230(01)00623-2. PMID   11750789. S2CID   271925.
  11. ↑ Vanover KE, Davis RE (28 July 2010). "Role of 5-HT2A receptor antagonists in the treatment of insomnia". Nature and Science of Sleep. 2: 139–150. doi: 10.2147/nss.s6849 . PMC   3630942 . PMID   23616706.
  12. ↑ Sanders-Bush E, Mayer SE (2006). "Chapter 11: 5-Hydroxytryptamine (Serotonin): Receptor Agonists and Antagonists". In Brunton LL, Lazo JS, Parker K (eds.). Goodman & Gilman's the Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. ISBN   0-07-142280-3.
  13. ↑ Siegel GJ, Albers RW (2005). Basic neurochemistry: molecular, cellular, and medical aspects. Vol. 1 (7th ed.). Academic Press. p. 241. ISBN   0-12-088397-X.
  14. ↑ Hoyer D, Hannon JP, Martin GR (April 2002). "Molecular, pharmacological and functional diversity of 5-HT receptors". Pharmacology, Biochemistry, and Behavior. 71 (4): 533–554. doi:10.1016/S0091-3057(01)00746-8. PMID   11888546. S2CID   25543069.
  15. ↑ Bonis J, Furlong LI, Sanz F (October 2006). "OSIRIS: a tool for retrieving literature about sequence variants". Bioinformatics. 22 (20): 2567–2569. doi: 10.1093/bioinformatics/btl421 . PMID   16882651. Supplementary material to article
  16. 1 2 Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (March 2001). "Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists". Journal of Medicinal Chemistry. 44 (6): 1003–1010. doi:10.1021/jm000491y. PMID   11300881.
  17. ↑ Goldstein AT, Pukall C, Goldstein IL (2020). "Fibromyalgia and Female Sexual Pain Disorders". Female Sexual Pain Disorders: Evaluation and Management (2 ed.). Wiley. ISBN   978-1119482666.
  18. 1 2 3 4 Ruble CL, Smith RM, Calley J, Munsie L, Airey DC, Gao Y, et al. (January 2016). "Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons". BMC Genetics. 17 (1) 16. doi: 10.1186/s12863-015-0325-6 . PMC   4702415 . PMID   26738766.
  19. ↑ Medrihan L, Sagi Y, Inde Z, Krupa O, Daniels C, Peyrache A, et al. (August 2017). "Initiation of Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus". Neuron. 95 (3): 564–576.e4. doi: 10.1016/j.neuron.2017.06.044 . PMID   28735749.
  20. ↑ Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC (March 2017). "Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome". Brain. 140 (3): 669–683. doi:10.1093/brain/aww342. PMC   6075536 . PMID   28073790.
  21. ↑ Giulietti M, Vivenzio V, Piva F, Principato G, Bellantuono C, Nardi B (July 2014). "How much do we know about the coupling of G-proteins to serotonin receptors?". Molecular Brain. 7 (1) 49. doi: 10.1186/s13041-014-0049-y . PMC   4105882 . PMID   25011628.
  22. ↑ Lal D, May P, Perez-Palma E, Samocha KE, Kosmicki JA, Robinson EB, et al. (March 2020). "Gene family information facilitates variant interpretation and identification of disease-associated genes in neurodevelopmental disorders". Genome Medicine. 12 (1) 28. doi: 10.1186/s13073-020-00725-6 . PMC   7079346 . PMID   32183904.
  23. ↑ Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan F, et al. (November 2020). "HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling". Cell Stress & Chaperones. 25 (6): 899–908. doi:10.1007/s12192-020-01124-x. PMC   7591670 . PMID   32519137.
  24. ↑ Cao X, Wang Y, Shu D, Qu H, Luo C, Hu X (October 2020). "Food intake-related genes in chicken determined through combinatorial genome-wide association study and transcriptome analysis". Animal Genetics. 51 (5): 741–751. doi:10.1111/age.12980. PMID   32720725. S2CID   220839883.
  25. ↑ Garza-Brenner E, Sifuentes-Rincón AM, Randel RD, Paredes-Sánchez FA, Parra-Bracamonte GM, Arellano Vera W, et al. (August 2017). "Association of SNPs in dopamine and serotonin pathway genes and their interacting genes with temperament traits in Charolais cows". Journal of Applied Genetics. 58 (3): 363–371. doi:10.1007/s13353-016-0383-0. PMID   27987181. S2CID   34463383.
  26. ↑ Cheah SY, Lawford BR, Young RM, Morris CP, Voisey J (January 2017). "mRNA Expression and DNA Methylation Analysis of Serotonin Receptor 2A (HTR2A) in the Human Schizophrenic Brain". Genes. 8 (1): 14. doi: 10.3390/genes8010014 . PMC   5295009 . PMID   28054990.
  27. ↑ Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS (March 2011). "Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association". Neuromolecular Medicine. 13 (1): 66–76. doi:10.1007/s12017-010-8138-2. PMC   3044825 . PMID   20941551.
  28. ↑ Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, et al. (February 2013). "Function of alternative splicing". Gene. 514 (1): 1–30. doi:10.1016/j.gene.2012.07.083. PMC   5632952 . PMID   22909801.
  29. ↑ Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, et al. (June 2015). "Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins". Genome Research. 25 (6): 858–871. doi:10.1101/gr.184390.114. PMC   4448682 . PMID   25883322.
  30. ↑ Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, Fisher PM, et al. (January 2017). "A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System". The Journal of Neuroscience. 37 (1): 120–128. doi:10.1523/JNEUROSCI.2830-16.2016. PMC   5214625 . PMID   28053035.
  31. ↑ Aghajanian GK, Marek GJ (April 1999). "Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release". Brain Research. 825 (1–2): 161–171. doi: 10.1016/S0006-8993(99)01224-X . PMID   10216183. S2CID   20081913.
  32. ↑ Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001). "A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex". Neuroscience. 105 (2): 379–392. doi:10.1016/S0306-4522(01)00199-3. PMID   11672605. S2CID   19764312.
  33. 1 2 3 Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F (December 2005). "The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity". Journal of Neurochemistry. 95 (6): 1597–1607. doi:10.1111/j.1471-4159.2005.03485.x. hdl: 10261/33026 . PMID   16277612. S2CID   18350703.
  34. ↑ Amargós-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, et al. (March 2004). "Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex". Cerebral Cortex. 14 (3): 281–299. doi: 10.1093/cercor/bhg128 . hdl: 10261/34683 . PMID   14754868.
  35. ↑ Feng J, Cai X, Zhao J, Yan Z (September 2001). "Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons". The Journal of Neuroscience. 21 (17): 6502–6511. doi:10.1523/JNEUROSCI.21-17-06502.2001. PMC   6763081 . PMID   11517239.
  36. ↑ Marek GJ (June 2009). "Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats". Neuropharmacology. 56 (8): 1082–1087. doi:10.1016/j.neuropharm.2009.03.005. PMC   2706691 . PMID   19324062.
  37. ↑ Zhang C, Marek GJ (January 2008). "AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (1): 62–71. doi:10.1016/j.pnpbp.2007.07.009. PMID   17728034. S2CID   44889209.
  38. ↑ Gewirtz JC, Marek GJ (November 2000). "Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors". Neuropsychopharmacology. 23 (5): 569–576. doi: 10.1016/S0893-133X(00)00136-6 . PMID   11027922.
  39. ↑ Marek GJ, Zhang C (September 2008). "Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex". Neuroscience Letters. 442 (3): 239–243. doi:10.1016/j.neulet.2008.06.083. PMC   2677702 . PMID   18621097.
  40. ↑ Lambe EK, Liu RJ, Aghajanian GK (November 2007). "Schizophrenia, hypocretin (orexin), and the thalamocortical activating system". Schizophrenia Bulletin. 33 (6): 1284–1290. doi:10.1093/schbul/sbm088. PMC   2779889 . PMID   17656637.
  41. ↑ Liu RJ, Aghajanian GK (January 2008). "Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy". Proceedings of the National Academy of Sciences of the United States of America. 105 (1): 359–364. Bibcode:2008PNAS..105..359L. doi: 10.1073/pnas.0706679105 . PMC   2224217 . PMID   18172209.
  42. ↑ Geurts FJ, De Schutter E, Timmermans JP (June 2002). "Localization of 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum". Journal of Chemical Neuroanatomy. 24 (1): 65–74. doi:10.1016/S0891-0618(02)00020-0. PMID   12084412. S2CID   16510169.
  43. ↑ Maeshima T, Shutoh F, Hamada S, Senzaki K, Hamaguchi-Hamada K, Ito R, et al. (August 1998). "Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells". Neuroscience Letters. 252 (1): 72–74. doi:10.1016/S0304-3940(98)00546-1. PMID   9756362. S2CID   28549709.
  44. ↑ Maeshima T, Shiga T, Ito R, Okado N (December 2004). "Expression of serotonin2A receptors in Purkinje cells of the developing rat cerebellum". Neuroscience Research. 50 (4): 411–417. doi:10.1016/j.neures.2004.08.010. PMID   15567478. S2CID   5772490.
  45. ↑ Dürk T, Panther E, Müller T, Sorichter S, Ferrari D, Pizzirani C, et al. (May 2005). "5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes". International Immunology. 17 (5): 599–606. doi: 10.1093/intimm/dxh242 . PMID   15802305.
  46. ↑ Johansen A, Holm S, Dall B, Keller S, Kristensen JL, Knudsen GM, et al. (July 2019). "Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions". EJNMMI Research. 9 (1) 71. doi: 10.1186/s13550-019-0527-4 . PMC   6669221 . PMID   31367837.
  47. 1 2 Shan J, Khelashvili G, Mondal S, Mehler EL, Weinstein H (2012). "Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties". PLOS Computational Biology. 8 (4): e1002473. Bibcode:2012PLSCB...8E2473S. doi: 10.1371/journal.pcbi.1002473 . PMC   3330085 . PMID   22532793.{{cite journal}}: CS1 maint: article number as page number (link)
  48. ↑ Chalit JE, Ragan EJ. The Serotonin G-Protein Coupled Receptor 5HT2A: Molecular and Multiple Sequence Analysis (PDF) (Report).
  49. ↑ Kimura KT, Asada H, Inoue A, Kadji FM, Im D, Mori C, et al. (February 2019). "Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine". Nature Structural & Molecular Biology. 26 (2): 121–128. doi:10.1038/s41594-018-0180-z. PMID   30723326.
  50. 1 2 3 4 Viohl N, Hakami Zanjani AA, Khandelia H (March 2025). "Molecular insights into the modulation of the 5HT2A receptor by serotonin, psilocin, and the G protein subunit Gqα". FEBS Letters. 599 (6): 876–891. doi:10.1002/1873-3468.15099. PMC   11931985 . PMID   39865564.
  51. 1 2 Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nature Communications. 14 (1) 8221. doi:10.1038/s41467-023-44016-1. PMC   10724237 . PMID   38102107.
  52. ↑ Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, et al. (March 2025). "The structural diversity of psychedelic drug actions revealed". Nature Communications. 16 (1) 2734. Bibcode:2025NatCo..16.2734G. doi:10.1038/s41467-025-57956-7. PMC   11923220 . PMID   40108183.
  53. ↑ Gumpper RH, DiBerto J, Jain M, Kim K, Fay J, Roth BL (September 2022). Structures of Hallucinogenic and Non-Hallucinogenic Analogues of the 5-HT2A Receptor Reveals Molecular Insights into Signaling Bias (PDF). University of North Carolina at Chapel Hill Department of Pharmacology Research Retreat September 16th, 2022 – William and Ida Friday Center. Recently, there has been a resurgence in utilizing classical psychedelics to treat depression, addiction, anxiety disorders, and cluster headaches. The biological target of these compounds, and the route of its therapeutic actions, is the 5HT2A receptor (5HT2AR). It has been hypothesized that the hallucinations and therapeutic actions can be separated through biased agonism and G-protein activation. Here we present 8 new cryoEM structures covering all major compound classes for the 5HT2AR including a novel arrestin biased compound RS130-180. Utilizing the structural and functional data we noticed a correlation between ligand bias and the placement of the canonical "toggle-switch" tryptophan. These findings lead to a broader mechanistic understanding of 5HT2AR activation as well as potential for the development of biased ligands.
  54. 1 2 3 Zhang G, Stackman RW (2015). "The role of serotonin 5-HT2A receptors in memory and cognition". Frontiers in Pharmacology. 6: 225. doi: 10.3389/fphar.2015.00225 . PMC   4594018 . PMID   26500553.
  55. 1 2 3 4 Raote I, Bhattacharya A, Panicker MM (2007). "Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways.". In Chattopadhyay A (ed.). Serotonin Receptors in Neurobiology. Frontiers in Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis. ISBN   978-0-8493-3977-6. PMID   21204452.
  56. ↑ Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (January 2007). "Functional selectivity and classical concepts of quantitative pharmacology". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID   16803859. S2CID   447937.
  57. 1 2 Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (April 2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neuroscience Letters. 493 (3): 76–79. doi:10.1016/j.neulet.2011.01.046. PMC   3064746 . PMID   21276828.
  58. 1 2 Jalal B (November 2018). "The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug". Psychopharmacology. 235 (11): 3083–3091. doi:10.1007/s00213-018-5042-1. PMC   6208952 . PMID   30288594.
  59. ↑ Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID   18708586. S2CID   25374241.
  60. ↑ Nau F, Yu B, Martin D, Nichols CD (2013). "Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo". PLOS ONE. 8 (10): e75426. Bibcode:2013PLoSO...875426N. doi: 10.1371/journal.pone.0075426 . PMC   3788795 . PMID   24098382.{{cite journal}}: CS1 maint: article number as page number (link)
  61. ↑ Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS (May 2001). "5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells". The Journal of Neuroscience. 21 (10): 3572–3579. doi:10.1523/JNEUROSCI.21-10-03572.2001. PMC   6762485 . PMID   11331386.
  62. ↑ Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D'Souza DN, Tetzlaff J, et al. (November 2002). "Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (−)DOI". The Journal of Neuroscience. 22 (21): 9635–9642. doi:10.1523/JNEUROSCI.22-21-09635.2002. PMC   6758011 . PMID   12417689.
  63. ↑ Harvey JA (2003). "Role of the serotonin 5-HT(2A) receptor in learning". Learning & Memory. 10 (5): 355–362. doi:10.1101/lm.60803. PMC   218001 . PMID   14557608.
  64. ↑ Williams GV, Rao SG, Goldman-Rakic PS, Foresta M, Ropolo M, Degan P, et al. (March 2010). "Defective repair of 5-hydroxy-2'-deoxycytidine in Cockayne syndrome cells and its complementation by Escherichia coli formamidopyrimidine DNA glycosylase and endonuclease III". Free Radical Biology & Medicine. 48 (5): 681–690. doi:10.1016/j.freeradbiomed.2009.12.007. PMC   6758292 . PMID   11923449.
  65. ↑ Passier A, van Puijenbroek E (November 2005). "Mirtazapine-induced arthralgia". British Journal of Clinical Pharmacology. 60 (5): 570–572. doi:10.1111/j.1365-2125.2005.02481.x. PMC   1884949 . PMID   16236049.
  66. ↑ Adwan MH (August 2016). "An update on drug-induced arthritis". Rheumatology International. 36 (8): 1089–1097. doi:10.1007/s00296-016-3462-y. PMID   27000044. S2CID   25401280.
  67. ↑ Herth MM, Knudsen GM (June 2015). "Current radiosynthesis strategies for 5-HT2A receptor PET tracers". Journal of Labelled Compounds & Radiopharmaceuticals. 58 (7): 265–273. doi:10.1002/jlcr.3288. PMID   25997728.
  68. ↑ Beer R (13 June 2023). "Anblick von toten Fliegen lässt Fliegen altern". science.ORF.at (in German). Retrieved 14 June 2023.
  69. ↑ Gendron CM, Chakraborty TS, Duran C, Dono T, Pletcher SD (June 2023). "Ring neurons in the Drosophila central complex act as a rheostat for sensory modulation of aging". PLOS Biology. 21 (6): e3002149. doi: 10.1371/journal.pbio.3002149 . PMC   10263353 . PMID   37310911.{{cite journal}}: CS1 maint: article number as page number (link)
  70. ↑ Nichols DE (February 2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–181. doi:10.1016/j.pharmthera.2003.11.002. PMID   14761703.
  71. ↑ Blaazer AR, Smid P, Kruse CG (September 2008). "Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors". ChemMedChem. 3 (9): 1299–1309. doi:10.1002/cmdc.200800133. PMID   18666267. S2CID   7537908.
  72. ↑ Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, et al. (December 2012). "Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function". The Journal of Biological Chemistry. 287 (53): 44301–44319. doi: 10.1074/jbc.M112.413161 . PMC   3531745 . PMID   23129762.
  73. ↑ González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. (March 2008). "Identification of a serotonin/glutamate receptor complex implicated in psychosis". Nature. 452 (7183): 93–97. Bibcode:2008Natur.452...93G. doi:10.1038/nature06612. PMC   2743172 . PMID   18297054.
  74. ↑ Taddeucci A, Olivero G, Roggeri A, Milanese C, Giorgio FP, Grilli M, et al. (September 2022). "Presynaptic 5-HT2A-mGlu2/3 Receptor-Receptor Crosstalk in the Prefrontal Cortex: Metamodulation of Glutamate Exocytosis". Cells. 11 (19): 3035. doi: 10.3390/cells11193035 . PMC   9562019 . PMID   36230998.
  75. ↑ Wingen M, Kuypers KP, Ramaekers JG (February 2007). "The role of 5-HT1a and 5-HT2A receptors in attention and motor control: a mechanistic study in healthy volunteers". Psychopharmacology. 190 (3): 391–400. doi:10.1007/s00213-006-0614-x. PMID   17124621. S2CID   25125461.
  76. ↑ Wingen M, Kuypers KP, Ramaekers JG (July 2007). "Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI". Journal of Psychopharmacology. 21 (5): 477–485. doi:10.1177/0269881106072506. PMID   17092965. S2CID   19575488.
  77. ↑ Nichols DE (April 2016). "Psychedelics". Pharmacol Rev. 68 (2): 264–355. doi:10.1124/pr.115.011478. PMC   4813425 . PMID   26841800.
  78. 1 2 3 4 Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID   38033123.
  79. ↑ Atiq MA, Baker MR, Voort JL, Vargas MV, Choi DS (May 2024). "Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties". Psychopharmacology (Berl). 242 (7): 1481–1506. doi: 10.1007/s00213-024-06599-5 . PMC   12226698 . PMID   38743110.
  80. ↑ Hinkle JT, Graziosi M, Nayak SM, Yaden DB (December 2024). "Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis". JAMA Psychiatry. 81 (12): 1225–1235. doi:10.1001/jamapsychiatry.2024.2546. PMC   11375525 . PMID   39230883.
  81. ↑ Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ (March 2022). "Adverse effects of psychedelics: From anecdotes and misinformation to systematic science". J Psychopharmacol. 36 (3): 258–272. doi:10.1177/02698811211069100. PMC   8905125 . PMID   35107059.
  82. ↑ Roth BL, Gumpper RH (May 2023). "Psychedelics as Transformative Therapeutics". Am J Psychiatry. 180 (5): 340–347. doi:10.1176/appi.ajp.20230172. PMID   37122272.
  83. ↑ Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (December 2023). "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders". Drug Discov Today. 28 (12) 103818. doi:10.1016/j.drudis.2023.103818. PMID   37925136.
  84. ↑ Nutt D, Spriggs M, Erritzoe D (February 2023). "Psychedelics therapeutics: What we know, what we think, and what we need to research". Neuropharmacology. 223 109257. doi: 10.1016/j.neuropharm.2022.109257 . PMID   36179919.
  85. 1 2 Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE (2021). "Psychedelics and Other Psychoplastogens for Treating Mental Illness". Front Psychiatry. 12 727117. doi: 10.3389/fpsyt.2021.727117 . PMC   8520991 . PMID   34671279.
  86. ↑ Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS (September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry". Psychedelic Medicine. 1 (3): 150–165. doi:10.1089/psymed.2023.0013. PMC   11661494 . PMID   40046566.
  87. ↑ Hatzipantelis CJ, Olson DE (February 2024). "The Effects of Psychedelics on Neuronal Physiology". Annu Rev Physiol. 86: 27–47. doi:10.1146/annurev-physiol-042022-020923. PMC   10922499 . PMID   37931171.
  88. ↑ Olson DE (February 2022). "Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity". Biochemistry. 61 (3): 127–136. doi:10.1021/acs.biochem.1c00812. PMC   9004607 . PMID   35060714.
  89. 1 2 3 Nichols DE, Johnson MW, Nichols CD (February 2017). "Psychedelics as Medicines: An Emerging New Paradigm". Clin Pharmacol Ther. 101 (2): 209–219. doi:10.1002/cpt.557. PMID   28019026.
  90. 1 2 3 4 5 Flanagan TW, Nichols CD (2022). "Psychedelics and Anti-inflammatory Activity in Animal Models". Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences. Vol. 56. pp. 229–245. doi:10.1007/7854_2022_367. ISBN   978-3-031-12183-8. PMID   35546383.
  91. 1 2 3 4 Nichols CD (November 2022). "Psychedelics as potent anti-inflammatory therapeutics". Neuropharmacology. 219 109232. doi: 10.1016/j.neuropharm.2022.109232 . PMID   36007854.
  92. 1 2 3 4 Flanagan TW, Nichols CD (August 2018). "Psychedelics as anti-inflammatory agents" (PDF). Int Rev Psychiatry. 30 (4): 363–375. doi:10.1080/09540261.2018.1481827. PMID   30102081.
  93. ↑ Thompson C, Szabo A (December 2020). "Psychedelics as a novel approach to treating autoimmune conditions". Immunol Lett. 228: 45–54. doi:10.1016/j.imlet.2020.10.001. hdl: 10852/80687 . PMID   33035575.
  94. ↑ Low ZX, Ng WS, Lim ES, Goh BH, Kumari Y (September 2024). "The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies". Prog Neuropsychopharmacol Biol Psychiatry. 136 111139. doi: 10.1016/j.pnpbp.2024.111139 . PMID   39251080.
  95. 1 2 3 4 5 Flanagan TW, Billac GB, Landry AN, Sebastian MN, Cormier SA, Nichols CD (April 2021). "Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore". ACS Pharmacol Transl Sci. 4 (2): 488–502. doi:10.1021/acsptsci.0c00063. PMC   8033619 . PMID   33860179.
  96. 1 2 Flanagan TW, Billac G, Nichols CD (2022). "Differential Regulation of Inflammatory Responses Following 5-HT 2 Receptor Activation in Pulmonary Tissues". The FASEB Journal. 36 (S1) fasebj.2022.36.S1.R2617. doi: 10.1096/fasebj.2022.36.S1.R2617 . ISSN   0892-6638.
  97. 1 2 3 Flanagan TW, Foster TP, Galbato TE, Lum PY, Louie B, Song G, et al. (February 2024). "Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression". ACS Pharmacology & Translational Science. 7 (2): 478–492. doi:10.1021/acsptsci.3c00297. PMC   10863441 . PMID   38357283. The effects of (R)-DOTFM were examined in the head-twitch response (HTR) assay. (R)-DOTFM produced a strong HTR with a potent ED 50 of 0.60 μmol/kg. These values are equivalent to (R)-DOI, as previously determined.
  98. ↑ Newvine C (8 July 2020). "Eleusis Draws on Research Into Psychedelics To Develop New Medicines for Inflammation". Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness. Retrieved 16 February 2025.
  99. ↑ Shlomi Raz, Eleusis (February 2020). Eleusis Drug Development Overview. LSX World Congress 2020.
  100. ↑ WOpublished 2020210823, Charles D. Nichols; Gerald Billac& David E. Nichols,"Compounds and methods for treating inflammatory disorders",published 15 October 2020
  101. ↑ Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, et al. (September 2019). "Microdosing psychedelics: More questions than answers? An overview and suggestions for future research". J Psychopharmacol. 33 (9): 1039–1057. doi:10.1177/0269881119857204. PMC   6732823 . PMID   31303095.
  102. ↑ Kinderlehrer DA (2025). "Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity". Neuropsychiatr Dis Treat. 21: 141–155. doi: 10.2147/NDT.S500337 . PMC   11787777 . PMID   39897712.
  103. ↑ Kozlowska U, Nichols C, Wiatr K, Figiel M (July 2022). "From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders". J Neurochem. 162 (1): 89–108. doi:10.1111/jnc.15509. PMID   34519052.
  104. ↑ Family N, Maillet EL, Williams LT, Krediet E, Carhart-Harris RL, Williams TM, et al. (March 2020). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers". Psychopharmacology (Berl). 237 (3): 841–853. doi:10.1007/s00213-019-05417-7. PMC   7036065 . PMID   31853557.
  105. 1 2 Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, et al. (July 2014). "Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36". Journal of Cerebral Blood Flow and Metabolism. 34 (7): 1188–1196. doi:10.1038/jcbfm.2014.68. PMC   4083382 . PMID   24780897.
  106. ↑ Braden MR, Parrish JC, Naylor JC, Nichols DE (December 2006). "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology. 70 (6): 1956–1964. doi:10.1124/mol.106.028720. PMID   17000863. S2CID   15840304.
  107. 1 2 Vasilkevich A, Halberstadt AL, Duan J, Merritt CR, Cunningham KA, McCorvy J, et al. (October 2024). Novel 5-HT2A selective agonists with well-characterized PK profile and short duration of action (PDF). Society for Neuroscience 2024 Annual Meeting (Chicago), October 5–9.
  108. ↑ Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, et al. (January 2017). "In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET radioligand in nonhuman primate". Bioorganic & Medicinal Chemistry Letters. 27 (1): 21–23. doi:10.1016/j.bmcl.2016.11.043. PMC   5348621 . PMID   27889455.
  109. ↑ Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, et al. (July 2003). "2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists". Bioorganic & Medicinal Chemistry Letters. 13 (14): 2369–2372. doi:10.1016/S0960-894X(03)00403-7. PMID   12824036.
  110. ↑ McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (September 2006). "1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists". Journal of Medicinal Chemistry. 49 (19): 5794–5803. doi:10.1021/jm060656o. PMID   16970404.
  111. ↑ Hansen M. Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Revised, Duplex print).pdf (Ph.D. thesis). University of Copenhagen – via Google Docs.
  112. ↑ Åstrand A, Guerrieri D, Vikingsson S, Kronstrand R, Green H (December 2020). "In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors-On-target receptor potency and efficacy, and off-target effects". Forensic Science International. 317 110553. doi: 10.1016/j.forsciint.2020.110553 . PMID   33160102.
  113. ↑ Vasilkevich A, Duan J, Lovera A, McCorvy J, Pedersen JT (October 2024). Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models (PDF). Society for Neuroscience 2024 Annual Meeting, Chicago, October 5–9.
  114. ↑ Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, et al. (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC   3547484 . PMID   23336049.
  115. ↑ Canal CE, Morgan D (July 2012). "Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model". Drug Testing and Analysis. 4 (7–8): 556–576. doi:10.1002/dta.1333. PMC   3722587 . PMID   22517680.
  116. ↑ Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, et al. (November 2013). "The HIV antiretroviral drug efavirenz has LSD-like properties". Neuropsychopharmacology. 38 (12): 2373–2384. doi:10.1038/npp.2013.135. PMC   3799056 . PMID   23702798.
  117. ↑ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579): 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID   35084960. S2CID   246360313.
  118. ↑ Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). "Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors". Psychopharmacology. 136 (4): 409–414. doi:10.1007/s002130050585. PMID   9600588. S2CID   3021798.
  119. ↑ Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, et al. (2006). "Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis". Clinical Neuropharmacology. 29 (2): 80–86. doi:10.1097/00002826-200603000-00005. PMID   16614540. S2CID   33849447.
  120. ↑ Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, et al. (July 2014). "Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro". Psychopharmacology. 231 (14): 2771–2783. doi:10.1007/s00213-014-3446-0. PMC   4097020 . PMID   24488404.
  121. ↑ de la Fuente Revenga M, Shah UH, Nassehi N, Jaster AM, Hemanth P, Sierra S, et al. (March 2021). "Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice". ACS Chemical Neuroscience. 12 (5): 831–844. doi:10.1021/acschemneuro.0c00291. PMC   7933111 . PMID   33400504.
  122. ↑ Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, et al. (July 2003). "2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists". Bioorganic & Medicinal Chemistry Letters. 13 (14): 2369–2372. doi:10.1016/s0960-894x(03)00403-7. PMID   12824036.
  123. ↑ Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, et al. (March 2005). "Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity". Bioorganic & Medicinal Chemistry Letters. 15 (5): 1467–1470. doi:10.1016/j.bmcl.2004.12.080. PMID   15713408.
  124. ↑ WO WO2007149728,Mohapatra S, Hellberg MR, Feng Z,"Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma", assigned to Alcon Manufacturing, Ltd.
  125. ↑ Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, et al. (January 2008). "Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity". Journal of Medicinal Chemistry. 51 (2): 305–313. doi:10.1021/jm0709034. PMID   18095642.
  126. ↑ Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, et al. (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". Journal of Medicinal Chemistry. 56 (3): 1211–1227. doi:10.1021/jm301656h. PMID   23301527.
  127. ↑ Orr MJ, Cao AB, Wang CT, Gaisin A, Csakai A, Friswold AP, et al. (April 2022). "Discovery of Highly Potent Serotonin 5-HT2 Receptor Agonists Inspired by Heteroyohimbine Natural Products". ACS Medicinal Chemistry Letters. 13 (4): 648–657. doi:10.1021/acsmedchemlett.1c00694. PMC   9014500 . PMID   35450369.
  128. ↑ Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, et al. (October 2022). "Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity". Nature. 610 (7932): 582–591. Bibcode:2022Natur.610..582K. doi:10.1038/s41586-022-05258-z. PMC   9996387 . PMID   36171289. S2CID   252598838.
  129. ↑ Lyu J, Kapolka N, Gumpper R, Alon A, Wang L, Jain MK, et al. (December 2023). "AlphaFold2 structures template ligand discovery". bioRxiv. doi:10.1101/2023.12.20.572662. PMC   10769324 . PMID   38187536.
  130. ↑ Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. (May 2021). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi: 10.1016/j.cell.2021.03.043 . PMC   8122087 . PMID   33915107.
  131. ↑ Märcher Rørsted E, Jensen AA, Kristensen JL (November 2021). "25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor". ChemMedChem. 16 (21): 3263–3270. doi:10.1002/cmdc.202100395. PMID   34288515.
  132. ↑ Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, et al. (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chem Neurosci. 4 (1): 96–109. doi:10.1021/cn3000668. PMC   3547484 . PMID   23336049.
  133. ↑ M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (May 2024). "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 67 (9): 7224–7244. doi:10.1021/acs.jmedchem.4c00082. PMC   11089506 . PMID   38648420.
  134. ↑ Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Marcher-Rorsted E, et al. (22 April 2024). "The selective 5-HT 2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents". bioRxiv. doi: 10.1101/2024.04.19.590212 .
  135. ↑ "LPH 48". AdisInsight. 22 May 2024. Retrieved 30 October 2024.
  136. ↑ Yuan H, Guo Z, Luo T (February 2017). "Synthesis of (+)-Lysergol and Its Analogues To Assess Serotonin Receptor Activity". Org Lett. 19 (3): 624–627. doi:10.1021/acs.orglett.6b03779. PMID   28106398.
  137. ↑ US 7655691,Kumaran G, Morency C, Roth B, Sard HP, Shuster L Xu L,"Indole compounds useful as serotonin selective agents.",published 11 May 2006, assigned to Organix Inc
  138. ↑ Motaghinejad O, Motaghinejad M, Motevalian M, Rahimi-Sharbaf F, Beiranvand T (October 2017). "The effect of maternal forced exercise on offspring pain perception, motor activity and anxiety disorder: the role of 5-HT2 and D2 receptors and CREB gene expression". Journal of Exercise Rehabilitation. 13 (5): 514–525. doi:10.12965/jer.1734992.496. PMC   5667597 . PMID   29114525.
  139. ↑ Sharif NA, McLaughlin MA, Kelly CR (February 2007). "AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist". Journal of Ocular Pharmacology and Therapeutics. 23 (1): 1–13. doi:10.1089/jop.2006.0093. PMID   17341144.
  140. ↑ May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA (January 2006). "1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity". Journal of Medicinal Chemistry. 49 (1): 318–328. doi:10.1021/jm050663x. PMID   16392816.
  141. ↑ Mestre TA, Zurowski M, Fox SH (April 2013). "5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders". Expert Opin Investig Drugs. 22 (4): 411–421. doi:10.1517/13543784.2013.769957. PMID   23409724.
  142. ↑ de Angelis L (January 2002). "5-HT2A antagonists in psychiatric disorders". Curr Opin Investig Drugs. 3 (1): 106–112. PMID   12054060.
  143. 1 2 Casey AB, Cui M, Booth RG, Canal CE (June 2022). ""Selective" serotonin 5-HT2A receptor antagonists". Biochem Pharmacol. 200 115028. doi:10.1016/j.bcp.2022.115028. PMC   9252399 . PMID   35381208.
  144. ↑ Brogden RN, Sorkin EM (December 1990). "Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease". Drugs. 40 (6): 903–949. doi:10.2165/00003495-199040060-00010. PMID   2079001.
  145. ↑ Badr B, Naguy A (October 2022). "Cyproheptadine: a psychopharmacological treasure trove?". CNS Spectr. 27 (5): 533–535. doi:10.1017/S1092852921000250. PMID   33632345.
  146. ↑ Badar A (2024). "Serotonin syndrome: An often-neglected medical emergency". J Family Community Med. 31 (1): 1–8. doi: 10.4103/jfcm.jfcm_236_23 . PMC   10883429 . PMID   38406216.
  147. ↑ King E, Rotella JA (February 2025). "Review article: Efficacy of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning - A systematic review". Emerg Med Australas. 37 (1) e14554. doi:10.1111/1742-6723.14554. PMID   39791184.
  148. ↑ Halman A, Kong G, Sarris J, Perkins D (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". J Psychopharmacol. 38 (1): 3–18. doi:10.1177/02698811231211219. PMC   10851641 . PMID   37982394.
  149. 1 2 Halberstadt AL, Nichols DE (2020). "Serotonin and serotonin receptors in hallucinogen action". Handbook of the Behavioral Neurobiology of Serotonin. Handbook of Behavioral Neuroscience. Vol. 31. pp. 843–863. doi:10.1016/B978-0-444-64125-0.00043-8. ISBN   9780444641250. ISSN   1569-7339. S2CID   241134396.
  150. ↑ Yates G, Melon E (January 2024). "Trip-killers: a concerning practice associated with psychedelic drug use" (PDF). Emerg Med J. 41 (2): 112–113. doi:10.1136/emermed-2023-213377. PMID   38123961. Archived from the original (PDF) on 11 May 2025.
  151. ↑ Shireman BT, Dvorak CA, Rudolph DA, Bonaventure P, Nepomuceno D, Dvorak L, et al. (March 2008). "2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists". Bioorganic & Medicinal Chemistry Letters. 18 (6): 2103–2108. doi:10.1016/j.bmcl.2008.01.090. PMID   18282705.
  152. ↑ Westkaemper RB, Runyon SP, Bondarev ML, Savage JE, Roth BL, Glennon RA (September 1999). "9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist". European Journal of Pharmacology. 380 (1): R5 –R7. doi:10.1016/S0014-2999(99)00525-7. PMID   10513561.
  153. ↑ Westkaemper RB, Glennon RA (June 2002). "Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands". Current Topics in Medicinal Chemistry. 2 (6): 575–598. doi:10.2174/1568026023393741. PMID   12052195. S2CID   23576058.
  154. ↑ Peddi S, Roth BL, Glennon RA, Westkaemper RB (December 2003). "Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist". European Journal of Pharmacology. 482 (1–3): 335–337. doi:10.1016/j.ejphar.2003.09.059. PMID   14660041.
  155. ↑ Runyon SP, Mosier PD, Roth BL, Glennon RA, Westkaemper RB (November 2008). "Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation". Journal of Medicinal Chemistry. 51 (21): 6808–6828. doi:10.1021/jm800771x. PMC   3088499 . PMID   18847250.
  156. ↑ Wilson KJ, van Niel MB, Cooper L, Bloomfield D, O'Connor D, Fish LR, et al. (May 2007). "2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands". Bioorganic & Medicinal Chemistry Letters. 17 (9): 2643–2648. doi:10.1016/j.bmcl.2007.01.098. PMID   17314044.
  157. ↑ Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K (April 2015). "Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors". European Neuropsychopharmacology. 25 (4): 505–511. doi: 10.1016/j.euroneuro.2015.01.014 . PMID   25687838.
  158. ↑ Das S, Barnwal P, Winston AB, Mondal S, Saha I (February 2016). "Brexpiprazole: so far so good". Therapeutic Advances in Psychopharmacology. 6 (1): 39–54. doi:10.1177/2045125315614739. PMC   4749739 . PMID   26913177.
  159. ↑ Rang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN   0-443-07145-4. Page 187
  160. 1 2 Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, et al. (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–240. doi:10.1007/bf02246453. PMID   8876023. S2CID   24889381.
  161. ↑ Marek GJ, Martin-Ruiz R, Abo A, Artigas F (December 2005). "The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine". Neuropsychopharmacology. 30 (12): 2205–2215. doi: 10.1038/sj.npp.1300762 . PMID   15886717.
  162. 1 2 Marcinkowska M, Kubacka M, Zagorska A, Jaromin A, Fajkis-Zajaczkowska N, Kolaczkowski M (January 2022). "Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif- as potential therapeutic agents in the prevention of cardiovascular diseases". Biomedicine & Pharmacotherapy. 145 112424. doi: 10.1016/j.biopha.2021.112424 . PMID   34785417. S2CID   244111116.
  163. ↑ Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, et al. (May 1999). "Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques". European Journal of Pharmacology. 372 (1): 49–56. doi:10.1016/S0014-2999(99)00114-4. PMID   10374714.
  164. ↑ Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T (October 2004). "Functions of 5-HT2A receptor and its antagonists in the cardiovascular system". Pharmacology & Therapeutics. 104 (1): 59–81. doi:10.1016/j.pharmthera.2004.08.005. PMID   15500909.
  165. ↑ Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, et al. (October 2001). "5-hydroxytryptamine2A receptor inverse agonists as antipsychotics". The Journal of Pharmacology and Experimental Therapeutics. 299 (1): 268–276. doi:10.1016/S0022-3565(24)29327-7. PMID   11561089.
  166. ↑ Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, et al. (September 2004). "Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist". The Journal of Pharmacology and Experimental Therapeutics. 310 (3): 943–951. doi:10.1124/jpet.104.066688. PMID   15102927. S2CID   12205122.
  167. ↑ Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. (December 2008). "APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep. 31 (12): 1663–1671. doi:10.1093/sleep/31.12.1663. PMC   2603489 . PMID   19090322.
  168. ↑ Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. (May 2006). "Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 910–918. doi:10.1124/jpet.105.097006. PMID   16469866. S2CID   22681576.
  169. ↑ Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, et al. (August 2007). "ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models". The Journal of Pharmacology and Experimental Therapeutics. 322 (2): 862–870. doi:10.1124/jpet.107.121715. PMID   17519387. S2CID   28861527.
  170. ↑ Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, et al. (October 2008). "A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model". Pharmacology, Biochemistry, and Behavior. 90 (4): 540–544. doi:10.1016/j.pbb.2008.04.010. PMC   2806670 . PMID   18534670.
  171. ↑ Abbas A, Roth BL (December 2008). "Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders". Expert Opinion on Pharmacotherapy. 9 (18): 3251–3259. doi:10.1517/14656560802532707. PMID   19040345. S2CID   71240383.
  172. ↑ Office of the Commissioner (10 September 2019). "FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease". FDA. Archived from the original on 7 September 2019.
  173. 1 2 3 4 Merritt C, Bolinger A, Anastasio N, Zhou J, Cunningham K (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P541 - P809: P722. Novel Positive Allosteric Modulators Augment 5-HT2A Receptor Functionality". Neuropsychopharmacology. 47 (Suppl 1): 371–520 (470–470). doi:10.1038/s41386-022-01486-z. PMC   9714408 . PMID   36456695.
  174. 1 2 3 4 5 Zamora JC, Merritt CR, Bolinger AA, Fox RG, Wild CT, Wold EA, et al. (2024). "Serendipitous Discovery of Novel 5-HT2AR Positive Allosteric Modulators (PAMs) Derived From 5-HT2CR PAM Scaffolds". The Journal of Pharmacology and Experimental Therapeutics. 389: 87. doi:10.1124/jpet.087.985400.
  175. ↑ Heng HL, Chee CF, Thy CK, Tee JT, Chin SP, Herr DR, et al. (February 2019). "In vitro functional evaluation of isolaureline, dicentrine and glaucine enantiomers at 5-HT2 and α1 receptors". Chem Biol Drug Des. 93 (2): 132–138. doi:10.1111/cbdd.13390. PMID   30216681.
  176. ↑ Brunetti L, Francavilla F, Leopoldo M, Lacivita E (May 2024). "Allosteric Modulators of Serotonin Receptors: A Medicinal Chemistry Survey". Pharmaceuticals (Basel). 17 (6): 695. doi: 10.3390/ph17060695 . PMC   11206742 . PMID   38931362. Several compounds of this series showed significant efficacy at 1 nM in improving 5-HT-mediated calcium efflux. Interestingly, while some of them were selective PAMs of 5-HT2CR, others were described as dual 5-HT2AR/5-HT2CR PAMs. None of these compounds were reported as PAMs of 5-HT2BR. A full characterization was conducted for dual PAM JPC0323 (Figure 6), which evoked a 44% increase in maximum 5-HT-induced Ca2+ intake and also showed negligible displacement at orthosteric binding sites of a number of GPCRs and transporters and exhibited favorable pharmacokinetic parameters. In rats, JPC0323 suppressed spontaneous ambulation in a 5-HT2CR-dependent manner, suggesting that the compound has a preference for 5-HT2CR over 5-HT2AR [75].
  177. ↑ Chen J, Garcia EJ, Merritt CR, Zamora JC, Bolinger AA, Pazdrak K, et al. (July 2023). "Discovery of Novel Oleamide Analogues as Brain-Penetrant Positive Allosteric Serotonin 5-HT2C Receptor and Dual 5-HT2C/5-HT2A Receptor Modulators". J Med Chem. 66 (14): 9992–10009. doi:10.1021/acs.jmedchem.3c00908. PMC   10853020 . PMID   37462530.
  178. ↑ Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, et al. (June 2007). "Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1054–1061. doi:10.1124/jpet.106.117507. PMID   17337633. S2CID   11651502.
  179. ↑ González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. (February 2007). "Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior". Neuron. 53 (3): 439–452. doi: 10.1016/j.neuron.2007.01.008 . PMID   17270739. S2CID   16309730.
  180. ↑ Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, et al. (October 2008). "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells". European Journal of Pharmacology. 594 (1–3): 32–38. doi:10.1016/j.ejphar.2008.07.040. PMID   18703043.
  181. ↑ Schmid CL, Raehal KM, Bohn LM (January 2008). "Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo". Proceedings of the National Academy of Sciences of the United States of America. 105 (3): 1079–1084. doi: 10.1073/pnas.0708862105 . PMC   2242710 . PMID   18195357.
  182. ↑ Abbas A, Roth BL (January 2008). "Arresting serotonin". Proceedings of the National Academy of Sciences of the United States of America. 105 (3): 831–832. Bibcode:2008PNAS..105..831A. doi: 10.1073/pnas.0711335105 . PMC   2242676 . PMID   18195368.
  183. ↑ Zhang G, Cheng J, McCorvy JD, Lorello PJ, Caldarone BJ, Roth BL, et al. (July 2017). "Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications". Journal of Medicinal Chemistry. 60 (14): 6273–6288. doi:10.1021/acs.jmedchem.7b00584. PMC   7374938 . PMID   28657744.
  184. 1 2 3 Blier P, El Mansari M (2013). "Serotonin and beyond: therapeutics for major depression". Philos Trans R Soc Lond B Biol Sci. 368 (1615): 20120536. doi:10.1098/rstb.2012.0536. PMC   3638389 . PMID   23440470.{{cite journal}}: CS1 maint: article number as page number (link)
  185. 1 2 3 Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, et al. (August 2022). "The Roles of Serotonin in Neuropsychiatric Disorders". Cell Mol Neurobiol. 42 (6): 1671–1692. doi:10.1007/s10571-021-01064-9. PMC   11421740 . PMID   33651238.
  186. ↑ Rothman RB, Baumann MH (April 2002). "Serotonin releasing agents. Neurochemical, therapeutic and adverse effects". Pharmacol Biochem Behav. 71 (4): 825–836. doi:10.1016/s0091-3057(01)00669-4. PMID   11888573.
  187. ↑ Rothman RB, Baumann MH (July 2002). "Therapeutic and adverse actions of serotonin transporter substrates". Pharmacol Ther. 95 (1): 73–88. doi:10.1016/s0163-7258(02)00234-6. PMID   12163129.
  188. ↑ Rothman RB, Baumann MH (2000). "Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects". Drug Development Research. 51 (2): 52–65. doi:10.1002/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H. ISSN   0272-4391.
  189. ↑ Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID   17017961.
  190. ↑ Dunlap LE, Andrews AM, Olson DE (October 2018). "Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine" (PDF). ACS Chem Neurosci. 9 (10): 2408–2427. doi:10.1021/acschemneuro.8b00155. PMC   6197894 . PMID   30001118.
  191. ↑ Oeri HE (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol. 35 (5): 512–536. doi:10.1177/0269881120920420. PMC   8155739 . PMID   32909493.
  192. ↑ Gillman PK (February 2010). "Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review". Headache. 50 (2): 264–272. doi:10.1111/j.1526-4610.2009.01575.x. PMID   19925619.
  193. ↑ Sun-Edelstein C, Tepper SJ, Shapiro RE (September 2008). "Drug-induced serotonin syndrome: a review". Expert Opin Drug Saf. 7 (5): 587–596. doi:10.1517/14740338.7.5.587. PMID   18759711.
  194. ↑ Chiew AL, Isbister GK (March 2025). "[Not Available]". Br J Clin Pharmacol (in French). 91 (3): 654–661. doi:10.1111/bcp.16152. PMC   11862804 . PMID   38926083.
  195. ↑ Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (December 1991). "Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats". Journal of Nuclear Medicine. 32 (12): 2266–2272. PMID   1744713.
  196. ↑ Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, et al. (1996). "[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography". Life Sciences. 58 (10): PL 187-PL 192. doi:10.1016/0024-3205(96)00013-6. PMID   8602111.
  197. ↑ Johansen A, Hansen HD, Svarer C, Lehel S, Leth-Petersen S, Kristensen JL, et al. (April 2018). "The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [11C]Cimbi-36 labeled in two positions". Journal of Cerebral Blood Flow and Metabolism. 38 (4): 659–668. doi:10.1177/0271678x17746179. PMC   5888860 . PMID   29215308.
  198. ↑ Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ (February 2004). "Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography". Biological Psychiatry. 55 (3): 217–224. doi:10.1016/j.biopsych.2003.08.015. PMID   14744461. S2CID   24849671.
  199. ↑ Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, et al. (November 1996). "Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging". Psychiatry Research. 68 (1): 11–22. doi:10.1016/S0925-4927(96)02806-5. PMID   9027929. S2CID   32317795.
  200. ↑ Meltzer CC, Smith G, Price JC, Reynolds CF, Mathis CA, Greer P, et al. (November 1998). "Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction". Brain Research. 813 (1): 167–171. doi:10.1016/S0006-8993(98)00909-3. PMID   9824691. S2CID   21884218.
  201. ↑ Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, et al. (March 2004). "A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables". NeuroImage. 21 (3): 1105–1113. doi:10.1016/j.neuroimage.2003.10.046. PMID   15006678. S2CID   24403109.
  202. ↑ Choi MJ, Lee HJ, Lee HJ, Ham BJ, Cha JH, Ryu SH, et al. (2004). "Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene". Neuropsychobiology. 49 (1): 38–41. doi:10.1159/000075337. PMID   14730199. S2CID   19528052.
  203. ↑ Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, et al. (May 1996). "Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group". Lancet. 347 (9011): 1294–1296. doi:10.1016/s0140-6736(96)90939-3. PMID   8622505. S2CID   8510590.
  204. ↑ Vaquero-Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernandez-Navarro P, Giner L, et al. (July 2008). "Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 147B (5): 645–649. doi:10.1002/ajmg.b.30642. PMID   18163387. S2CID   31504282.
  205. ↑ Gene Overview of All Published Schizophrenia-Association Studies for HTR2A Archived 21 February 2009 at the Wayback Machine – SzGene database at Schizophrenia Research Forum.
  206. ↑ Serretti A, Drago A, De Ronchi D (2007). "HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies". Current Medicinal Chemistry. 14 (19): 2053–2069. doi:10.2174/092986707781368450. PMID   17691947.
  207. ↑ Maple AM, Zhao X, Elizalde DI, McBride AK, Gallitano AL (July 2015). "Htr2a Expression Responds Rapidly to Environmental Stimuli in an Egr3-Dependent Manner". ACS Chemical Neuroscience. 6 (7): 1137–1142. doi:10.1021/acschemneuro.5b00031. PMC   4565721 . PMID   25857407.
  208. 1 2 Williams AA, Ingram WM, Levine S, Resnik J, Kamel CM, Lish JR, et al. (September 2012). "Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine". Neuropsychopharmacology. 37 (10): 2285–2298. doi:10.1038/npp.2012.81. PMC   3422493 . PMID   22692564.
  209. ↑ Latorre E, Mesonero JE, Harries LW (November 2019). "Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders". Journal of Psychopharmacology. 33 (11): 1352–1363. doi:10.1177/0269881119856546. PMID   31210090. S2CID   190531249.
  210. ↑ Spies M, Nasser A, Ozenne B, Jensen PS, Knudsen GM, Fisher PM (November 2020). "Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels". Human Brain Mapping. 41 (16): 4518–4528. doi:10.1002/hbm.25138. PMC   7555071 . PMID   32697408.
  211. ↑ Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, et al. (June 2016). "Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach". Neuropharmacology. 105: 142–153. doi:10.1016/j.neuropharm.2015.12.022. PMID   26764241. S2CID   15031564.
  212. ↑ Ghasemi A, Seifi M, Baybordi F, Danaei N, Samadi Rad B (June 2018). "Association between serotonin 2A receptor genetic variations, stressful life events and suicide". Gene. 658: 191–197. doi:10.1016/j.gene.2018.03.023. PMID   29526601. S2CID   4854262.
  213. ↑ Videtic A, Pungercic G, Pajnic IZ, Zupanc T, Balazic J, Tomori M, et al. (September 2006). "Association study of seven polymorphisms in four serotonin receptor genes on suicide victims". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 141B (6): 669–672. doi:10.1002/ajmg.b.30390. PMID   16856120. S2CID   9279191.
  214. ↑ Laje G, McMahon FJ (December 2007). "The pharmacogenetics of major depression: past, present, and future". Biological Psychiatry. 62 (11): 1205–1207. doi:10.1016/j.biopsych.2007.09.016. PMID   17949692. S2CID   37225993.
  215. ↑ Leamy TE, Connor JP, Voisey J, Young RM, Gullo MJ (December 2016). "Alcohol misuse in emerging adulthood: Association of dopamine and serotonin receptor genes with impulsivity-related cognition". Addictive Behaviors. 63: 29–36. doi:10.1016/j.addbeh.2016.05.008. PMID   27399274.
  216. ↑ Jakubczyk A, Wrzosek M, Lukaszkiewicz J, Sadowska-Mazuryk J, Matsumoto H, Sliwerska E, et al. (January 2012). "The CC genotype in HTR2A T102C polymorphism is associated with behavioral impulsivity in alcohol-dependent patients". Journal of Psychiatric Research. 46 (1): 44–49. doi:10.1016/j.jpsychires.2011.09.001. PMC   3224206 . PMID   21930285.
  217. ↑ da Silva Junior FC, Araujo RM, Sarmento AS, de Carvalho MM, Fernandes HF, Yoshioka FK, et al. (December 2020). "The association of A-1438G and T102C polymorphisms in HTR2A and 120 bp duplication in DRD4 with alcoholic dependence in a northeastern Brazilian male population". Gene Reports. 21 100889. doi:10.1016/j.genrep.2020.100889. S2CID   224859807.
  218. ↑ Land MA, Ramesh D, Miller AL, Pyles RB, Cunningham KA, Moeller FG, et al. (10 June 2020). "Methylation Patterns of the HTR2A Associate With Relapse-Related Behaviors in Cocaine-Dependent Participants". Frontiers in Psychiatry. 11 532. doi: 10.3389/fpsyt.2020.00532 . PMC   7299072 . PMID   32587535.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.